B7-33 and Telmisartan Interaction
B7-33 and Telmisartan have a synergistic interaction with 95% confidence. Potential synergistic effects for cardiac protection; both target complementary pathways involved in cardiac remodeling and fibrosis. Both compounds affect the heart, so monitoring these systems is recommended.
Compound Profiles
B7-33
Relaxin-2 Analog | Anti-Fibrotic & Cardiovascular
Selectively activates RXFP1, the primary receptor for relaxin-2, triggering downstream signaling cascades that inhibit fibroblast activation and collagen deposition, promote extracellular matrix remodeling via increased matrix metalloproteinase (MMP) activity, enhance nitric oxide-mediated vasodilation, and reduce inflammatory cytokine expression. B7-33 appears to preferentially engage pERK1/2 signaling pathways while showing reduced cAMP activation compared to native relaxin-2, suggesting biased agonism at RXFP1.
View full profileTelmisartan
Angiotensin II Receptor Blocker | Cardiac Protection On Cycle
Telmisartan selectively blocks the angiotensin II type 1 (AT1) receptor, preventing angiotensin II from exerting its vasoconstrictive, aldosterone-secreting, and pro-fibrotic effects. By antagonizing AT1, telmisartan lowers systemic vascular resistance and blood pressure while simultaneously reducing pathological cardiac and vascular remodeling.
View full profileCombined Organ Load
Shared Safety Flags
Frequently Asked Questions
Can I take B7-33 with Telmisartan?
Yes, B7-33 and Telmisartan can generally be taken together. Potential synergistic effects for cardiac protection; both target complementary pathways involved in cardiac remodeling and fibrosis.
Is B7-33 and Telmisartan safe together?
Based on documented research, this combination is considered synergistic. However, shared safety flags include: teratogenic. Monitor accordingly.
What are the interactions between B7-33 and Telmisartan?
Potential synergistic effects for cardiac protection; both target complementary pathways involved in cardiac remodeling and fibrosis. This assessment has 95% confidence and is based on documented research data.
How should I time B7-33 and Telmisartan?
B7-33 has a half-life of Not well characterized and Telmisartan has a half-life of ~24 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.
This interaction analysis is compiled from research literature and pharmacological mechanism data. Always consult a healthcare professional before combining compounds.